Biomarkers of Thrombosis in ST-Segment Elevation Myocardial Infarction : A Substudy of the ATOLL Trial Comparing Enoxaparin Versus Unfractionated Heparin

Publié dans American Journal of Cardiovascular Drugs 2018 Aug;18(6):503–511 Auteurs : Silvain J, O'Connor SA, Yan Y, Kerneis M, Hauguel-Moreau M, Zeitouni M, Overtchouk P, Ankri A, Brugier D, Vicaut E, Ecollan P, Galier S, Collet JP, Montalescot G; ATOLL Investigators. Article disponible en consultant le site Abstract Background and aim : The aim was…

Can a stable coronary artery disease patient be at high ischaemic risk for scheduled non-cardiac surgery ?

Publié dans Anaesthesia Critical Care & Pain Medicine 2018 August;37(4):313-315 Auteurs : Lattuca B, Cayla G, Montalescot G. Article disponible en consultant le site Abstract Article : With the increasing proportion of elderly patients, the prevalence of coronary artery disease (CAD) and, concomitantly, of stented arteries, continue to rise in everyday practice. Thus, the incidence…

Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis : The randomized ATLANTIS trial

Publié dans American Heart Journal 2018 June;200:40-50 Auteurs : Collet JP, Berti S, Cequier A, Van Belle E, Lefevre T, Leprince P, Neumann FJ, Vicaut E, Montalescot G. Article disponible en consultant le site Abstract Background and aim : Antithrombotic treatment regimen following transcatheter aortic valve replacement (TAVR) is not evidence-based. Apixaban, a non-vitamin K…

The times they are a changin’

Publié dans European Heart journal 2018 May; 39(19):1736-1739 Auteurs : Hammoudi N, Montalescot G Article disponible en consultant le site Abstract This editorial refers to "Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials" (link), by H.B.…